Application

Research CategoryApoptosis & Cancer

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected PEPCK in human kidney, human pancreas, human skeletal muscle, and human placental tissue.

Western Blotting Analysis: 2 µg/mL from a representative lot detected PEPCK in 10 µg of human kidney tissue.

Detect Phosphoenolpyruvate carboxykinase, cytosolic [GTP] using this rabbit polyclonal Anti-PEPCK, Cat. No. ABC1691, tested in Immunohistochemistry (Paraffin) and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Phosphoenolpyruvate carboxykinase, cytosolic (UniProt: also known as PEPCK, PEPCK-C) is encoded by the PCK1 (also known as PEPCK1) gene (Gene ID: 5105) in human. PEPCK catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), which is a rate-limiting step in gluconeogenesis. It requires manganese as a cofactor. It is expressed in higher levels in liver of fasting subjects. Kidney and adipocytes exhibit lower expression levels. Two isozymes of PEPCK have been identified, cytosolic and mitochondrial. PEPCK consists of an N-terminal and a catalytic C-terminal domain, with the active site and metal ions located in a cleft between them. Upon binding to substrate, PEPCK undergoes a conformational change that accelerates the catalysis process. Expression of PEPCK can be controlled by cAMP, glucocorticoids, and by insulin. Its expression is induced by glucagon, catecholamines, and glucocorticoids during periods of fasting and in response to stress and is diminished following glucose-induced and by the action of insulin. PEPCK-C is absent in fetal liver but appears at birth, concomitant with the capacity for gluconeogenesis. Deficiency of PEPCK-C is a rare metabolic disorder results in fatty infiltration of liver and kidney, hypoglycemia, hepatomegaly, and failure to thrive.

Immunogen

KLH-conjugated linear peptide corresponding to 15 amino acids from the C-terminal half of human phosphoenolpyyruvate carboxykinase (PEPCK).

Other Notes

Concentration: Please refer to lot specific datasheet.

Physical form

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Affinity Purified

Quality

Evaluated by Immunohistochemistry in human liver tissue

Immunohistochemistry Analysis: A 1:1,000 dilution of this antibody detected PEPCK in human liver tissue.

Specificity

This polyclonal antibody detects cytosolic phosphoenolpyruvate carboxykinase in human kidney.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Target description

~65 kDa observed; 69.19 kDa calculated. Uncharacterized bands may be observed in some lysate(s).